Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial

Pediatric Infectious Disease Journal

Volumn 15, Issue 12, 1996, Pages 1107-1112

  Driessen, Maeié ^a,c   Ellis, Jeff B ^a   Cooper, Peter A ^b   Wainer, Stephen ^b   Muwazi, Faith ^a   Hahn, Deidre ^b   Gous, Hermien ^b   De Villiers, François P R ^a  

^a Ga Rankuwa Hospital   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

amphotericin B; Fluconazole; fungal septicemia; neonates; randomized trial

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FUNGUS CULTURE; HUMAN; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NEWBORN; NEWBORN SEPSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOPHLEBITIS; VOMITING;

EID: 0030457165     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199612000-00011     Document Type: Article

References (27)

1. Viscoli C, Castagnola E, Fioreddo F, Ciravegna B, Barigione G, Terragna A. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991;35:365-7.
2. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(Suppl 3):S318-26.
3. Brammer KW, Tarbit MH. A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man. In: Fromtling RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Paris; Prous, 1987:141-9.
4. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990; 12(Suppl 3):S349-63.
5. Viscoli C, Castagnola E, Corsini M, Gastaldi R, Soliani M, Terragna A. Fluconazole therapy in an underweight infant. Eur J Clin Microbiol Infect Dis 1989;8:925-6.
6. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12:239S-247S.
7. Marriot MS, Richardson K. The discovery and mode of action of fluconazole.In: Fromtling RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Paris: Prous, 1987:81-92.
8. Foulds G, Wajszczuk C, Weidler DJ, Garg DC, Gibson P. Steady state parenteral kinetics of fluconazole in man [Abstract]. Presented at the First International Conference on Drug Research in Immunologic and Infectious Diseases-antifungal drugs: synthesis, preclinical and clinical evaluation, New York, October, 1987.
9. Troke PF. Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infection. In: Fromtling RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Paris: Prous, 1987:103-12.
10. Diamond RD, Saunders C, Sugar AM. Fluconazole therapy of serious Candida infections. In: Abstracts of the Tenth Congress of the International Society of Human and Animal Mycology, Barcelona, June, 1988.
11. Krzeska I, Yeates RA, Pfaff G. Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs Exp Clin Res 1993; 29:267-71.
12. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh T. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. Pediatrics 1992;120:987-93.
13. Bode S, Pedersen-Bjergaard L, Hjelt K. Candida albicans septicemia in a premature infant successfully treated with oral fluconazole. Scand J Infect Dis 1992;24:673-5.
14. Butler KM, Rench MA, Baker DJ. Amphotericin B as a single agent in the treatment of candidiasis in neonates. Pediatr Infect Dis J 1990;9:51-6.
15. Sugar AM, Stern JJ, Dupont B. Overview: treatment of crytococcal meningitis. Rev Infect Dis 1990;12(Suppl 3): S338-48.
16. Bristol-Myers Squibb (Pty) Ltd. Data sheet. Fungizone intravenous.
17. Roche Products (Pty) Ltd. Data sheet. Alcobon Roche.
18. Butler WT, Bennett JE, Ailing DW, Wertlake PT, Utz JP, Hill GJ III. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964;61:175-87.
19. Utz JP (moderator). Amphotericin B toxicity. Ann Intern Med 1964;61:334-54.
20. Dupont B, Drouhet E. Cryptococcal meningitis and fluconazole [Letter]. Ann Intern Med 1987;106:778.
21. Brammer KW, Farrow PR, Feczko JM. Fluconazole, a new systemically effective antifungal agent, for use in hospitalized patients [Abstract]. In: Proceedings of the First International Conference of the Hospital Infection Society, London, August, 1987.
22. Meunier F, Aoun M. Fluconazole: an alternative to treat fungemia? In: Abstracts of the Tenth Congress of the International Society of Human and Animal Mycology, Barcelona, June, 1988.
23. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980;302:145-55.
24. Hunt-Fugate AK, Hennessey CK, Kazarian CM. Stability of fluconazole in injectable solutions. Am J Hosp Pharm 1993;50:1186-7.
25. Epelbaum S, Laurent C, Morin G, Berquin P, Piussan C. Failure of fluconazole treatment in Candida meningitis. J Pediatr 1993;123:168-9.
26. Walsh TJ, Lee JW, Seibel N, Pizzo PA. Reply to the Editor regarding "failure of fluconazole treatment in Candida meningitis." J Pediatr 1993;123:168-9.
27. Buxton MJ, Dubois DJ, Turner RR, Sculpher MJ, Robinson PA, Searcy C. Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis: comparison of fluconazole and amphotericin B-based therapies. J Infect 1991;23:17-31.